ABOUT THIS STUDY
- Diagnosis of necrotizing pancreatitis within 120 hours following onset of symptoms/first reported symptoms.
- Primary diagnosis to be confirmed by contrast-enhanced CT evidence of 30% necrosis of the pancreas.
- Or if > or equal to 30% necrosis is not present or cannot be confirmed, a contrast enhanced CT scan showing extensive or multiple pancreatic fluid collections and pancreatic edema (Balthazar Grade E) with either C-reactive protein (CRP). 120 mg/L or a MOD score of > 2 is acceptable.
- Received an investigational drug or device within 30 days prior to entering study.
- Received > 48 hours of antibiotic therapy between onset of symptoms of pancreatitis
and diagnosis of necrotizing pancreatitis.
- The subject has known or suspected anaphylactic or other type 1 (immediate)
hypersensitivity reactions to cephalosporins, penicillins or carbapenems.
- The subject is receiving, or will require, probenecid therapy.
- The subject is neutropenic (absolute neutrophil count < 1000/mm 3).
- The subject has cirrhosis, severity of Child's grade C.
- There is not a commitment on the part of the clinical care team, the subject, or the
subject's family to full, aggressive support including operative intervention if
- The subject is a pregnant and/or nursing female
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- San Francisco, California
- Tampa, Florida
- Chicago, Illinois
- Baltimore, Maryland
- Boston, Massachusetts
- Worcester, Massachusetts
- Newark, New Jersey
- New York, New York
- Seattle, Washington
- Toronto, Ontario
- Montreal, Quebec